Time point | Group 1 (N = 117) | Group 2 (N = 119) | ||||
---|---|---|---|---|---|---|
n | GMT (95% CI) | Seropositive, % (95% CI) | n | GMT (95% CI) | Seropositive, % (95% CI) | |
Serotype 1 | ||||||
Baseline | 117 | 5.38 (4.85–5.96) | 1.7 (0.2–6.0) | 119 | 5.13 (4.98–5.28) | 2.5 (0.5–7.2) |
28 days post-dose 3 | 93 | 14.8 (11.3–19.4) | 52.7 (42.1–63.1) | 108 | 15.9 (12.6–20.0) | 56.5 (46.6–66.0) |
6 months post-dose 3 | 88 | 13.3 (10.2–17.4) | 47.7 (37.0–58.6) | 104 | 9.01 (7.54–10.8) | 32.7 (23.8–42.6) |
Serotype 2 | ||||||
Baseline | 117 | 5.19 (4.82–5.58) | 0.9 (0.0–4.7) | 119 | 5.22 (4.96–5.50) | 2.5 (0.5–7.2) |
28 days post-dose 3 | 94 | 51.2 (38.2–68.6) | 84.0 (75.0–90.8) | 108 | 59.9 (45.8–78.4) | 88.0 (80.3–93.4) |
6 months post-dose 3 | 88 | 45.6 (31.6–65.6) | 75.0 (64.6–83.6) | 104 | 38.7 (29.5–50.8) | 80.8 (71.9–87.8) |
Serotype 3 | ||||||
Baseline | 117 | 5.32 (4.94–5.73) | 2.6 (0.5–7.3) | 119 | 5.28 (5.03–5.55) | 4.2 (1.4–9.5) |
28 days post-dose 3 | 94 | 45.7 (35.0–59.8) | 85.1 (76.3–91.6) | 107 | 59.3 (47.0–74.7) | 90.7 (83.5–95.4) |
6 months post-dose 3 | 88 | 30.2 (22.8–40.2) | 79.5 (69.6–87.4) | 104 | 34.5 (27.5–43.3) | 80.8 (71.9–87.8) |
Serotype 4 | ||||||
Baseline | 117 | 5.78 (5.16–6.48) | 6.8 (3.0–13.0) | 119 | 5.11 (4.90–5.33) | 0.8 (0.0–4.6) |
28 days post-dose 3 | 94 | 66.8 (50.9–87.8) | 88.3 (80.0–94.0) | 107 | 83.1 (61.4–112.0) | 86.0 (77.9–91.9) |
6-months post-dose 3 | 88 | 74.8 (54.9–102.0) | 86.4 (77.4–92.8) | 104 | 41.7 (31.2–55.9) | 74.0 (64.5–82.1) |
≥ 3 serotypes | ||||||
Baseline | 117 | NA | 0.9 (0.0–4.7) | 119 | NA | 0.8 (0.0–4.6) |
28 days post-dose 3 | 94 | NA | 73.4 (63.3–82.0) | 108 | NA | 82.4 (73.9–89.1) |
6-months post-dose 3 | 88 | NA | 64.8 (53.9–74.7) | 104 | NA | 58.7 (48.6–68.2) |
All 4 serotypes | ||||||
Baseline | 117 | NA | 0.9 (0.0–4.7) | 119 | NA | 0.8 (0.0–4.6) |
Post-dose 3 | 94 | NA | 50.0 (39.5–60.5) | 108 | NA | 42.6 (33.1–52.5) |
6-months post-dose 3 | 88 | NA | 43.2 (32.7–54.2) | 104 | NA | 26.9 (18.7–36.5) |